Shares of $CAPR Capricor Therapeutics Inc. have been volatile recently as the company navigates a challenging FDA review for its Duchenne muscular dystrophy treatment, deramiocel. Although the latest 24-month open-label extension data from the HOPE-3 trial showed a significant slowing of upper limb decline—patients starting deramiocel after a year on placebo experienced a 76% reduction in deterioration, and those on continuous treatment maintained similar benefits—investor confidence remains cautious. The FDA advisory panel’s earlier rejection of deramiocel for cardiomyopathy has cast a shadow, with some analysts expecting a Complete Response Letter despite the new data strengthening the drug’s efficacy story. Capricor has responded by amending its Biologics License Application to focus on the upper limb skeletal muscle indication, which aligns more closely with the trial’s primary endpoint, but this shift has extended the regulatory timeline and added uncertainty.
Financially, Capricor reported a widening net loss and a decrease in cash reserves as it ramps up research and development and prepares for a potential launch. The company’s strategic pivot to emphasize the upper limb benefit reflects an effort to address FDA concerns and salvage approval prospects ahead of the November 22 PDUFA date. While some investors and analysts view the amended application and longer-term data as a positive step, skepticism remains given the FDA’s prior critical review and the complexities of the open-label extension data. As the FDA continues its evaluation, Capricor’s stock has experienced sharp swings, reflecting the high stakes and regulatory uncertainty surrounding deramiocel’s future.
Did you know?
Stocks of biotech companies often react strongly to FDA decisions because regulatory approval can make or break the commercial success of a drug, sometimes causing price swings of 50% or more in a single day.
Disclaimer
This content is for entertainment and discussion purposes only. It is based on publicly available headlines and social media commentary, which can be messy and ever-evolving. We are not financial advisors, and this is not investment advice. The publisher may hold positions in securities mentioned. We aim to keep things accurate—if you catch something off, please let us know.
Powered by - Trading Watch Premium
This data is 100% free and is made possible by our Monthly Supporters.
No Comments